UEG Week 2024

Abstract

Section snippets

Cendakimab for eosinophilic oesophagitis

Cendakimab, a monoclonal antibody that inhibits IL-13 binding to both IL-13Rα1 and IL-13Rα2, improved 24-week outcomes in patients with eosinophilic oesophagitis, according to data presented by Alain M Schoepfer (Lausanne, Switzerland). In a phase 3 trial, adults and adolescents with active eosinophilic oesophagitis were randomly assigned to receive subcutaneous cendakimab at 360 mg every week for 48 weeks (n=143), cendakimab 360 mg every week for 24 weeks followed by the same dose every other

TUSCANY-2

RO7790121, an anti-TL1A monoclonal antibody, could improve outcomes for patients with moderately to severely active ulcerative colitis who have failed previous treatment, according to results from the phase 2B TUSCANY-2 trial, presented by Silvio Danese (Milan, Italy). In this dose-ranging trial, patients were randomly assigned to receive RO7790121 subcutaneously once a month at 50 mg, 150 mg, or 450 mg, or placebo once a month for a 12-week induction period; in the 40-week treat-through

SHINE-1

In the phase 2 SHINE-1 trial, paediatric patients (2 to <18 years) with moderate-to-severe ulcerative colitis who had an inadequate response, loss of response, or intolerance to previous treatment, or who had corticosteroid-dependent colitis, were treated with mirikizumab at a dose determined by bodyweight. Patients with a clinical response per modified Mayo score at week 12 entered a maintenance period, receiving subcutaneous mirikizumab every 4 weeks (with dose again determined by patient

Partially hydrolysed guar gum for chronic constipation

Partially hydrolysed guar gum, a water-soluble fibre derived from guar seed, resulted in greater improvements in frequency of spontaneous bowel movements than did placebo after 6 weeks among patients with functional constipation or IBS-constipation. In a double-blind randomised trial presented by Sílvia Delgado-Aros (Vervey, Switzerland), participants were randomly assigned to receive partially hydrolysed guar gum (10 g/day) or placebo (80 patients in each group). At 6 weeks, patients in the